Steroid resistant nephrotic syndrome. Nephrotic syndrome with focal and segmental glomerular lesions
Conditions
Interventions
Intervention group: Approximately 5 to 7 cycles of plasmapheresis using 20% ??albumin (50 g/L albumin of plasma replacement) will be performed on patients with nephrotic syndrome. The therapeutic dose
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with nephrotic syndrome with the approved diagnosis of FSGS via renal biopsy samples Patients with refractory nephrotic syndrome despite recent treatments Patients with eGFR above 45 ml/min/1.73m2 before starting plasmapheresis
Exclusion criteria
Exclusion criteria: Patients with secondary FSGS caused by obesity, viral diseases, and medications Patients with genetic or familial FSGS Unwillingness to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alterations of serum albumin levels among patients with steroid-resistant nephrotic syndrome. Timepoint: Before and after starting plasmapheresis. Method of measurement: Bromcresol Purple (BCP) assay.;Proteinuria alterations among patients with steroid-resistant nephrotic syndrome. Timepoint: Before and after starting plasmapheresis. Method of measurement: Measurement of urine protein to creatinine ratio (UPCR) in morning urine samples.;EGFR alterations among patients with steroid-resistant nephrotic syndrome. Timepoint: Before and after starting plasmapheresis. Method of measurement: Via CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammadreza Ardalan
Tabriz University of Medical Sciences
Outcome results
None listed